neurotechnology/neuromodulation · experimental
Reference snapshot
This snapshot describes the state of the editorial record, not a diagnosis or a recommendation to intervene.
Claim ledger
These are declared editorial claim-to-source mappings. A mapping does not establish independent verification of the claim or its support. Citation controls open the corresponding source record.
Signal
MRI-guided tFUS can produce measurable target-engagement signals and is feasible for selected human research protocols.
Boundary
Target, skull geometry, acoustic dose, sham quality, operator expertise, and clinical indication determine what can be inferred.
Not established
Early target engagement does not establish consumer brain enhancement or safe home ultrasound use.
Mechanism map (working model)
A simplified causal map for orientation; it is not a diagnosis or a deterministic prediction.
Input or intervention
Imaging-guided acoustic exposure with defined target, frequency, intensity, geometry, and sham
Biological pathway
Mechanical neuromodulation of a selected neural target and downstream network response
Measurable signal
Target engagement, functional outcome, acoustic dosimetry, adverse events, and durable follow-up
Boundary
A consumer ultrasound device or acute neural signal is not equivalent to a validated clinical protocol.
Research appraisal checklist
Evidence to prioritize
Mechanistic work plus independent replication, well-described human feasibility or clinical studies, regulatory context, and long-term safety evidence. Regulatory status, contraindications, specialist oversight, and a credible stop or adverse-event pathway are part of the evidence—not optional extras.
Outcome anchor
Require transfer to real-world function, not only engagement, immersion, stimulation sensation, or an algorithmic performance score.
Main uncertainty
The main uncertainty is translation: whether the intervention can be delivered safely, reproducibly, and usefully in the intended human population.
What would change the conclusion
Upgrade confidence only when independent studies reproduce the result and make harms, adherence, and durability visible.
Minimum diligence questions
- Are the intervention, dose or exposure, comparator, population, and measurement conditions clearly defined?
- Do the outcomes matter outside the experiment, and are missing data, adverse events, and conflicts visible?
- Can the result be reproduced independently, and does it justify the level of risk being discussed?
Application and translation pathway
Current application boundary
Specialist research and early clinical development; not a consumer brain-optimization protocol.
Research and applied uses
- Deep-target neuromodulation
- Pain and movement-disorder research
- Mood and anxiety target-engagement studies
A staged map for separating an interesting mechanism from a reproducible, useful, and responsibly deployable application.
Target
Specify anatomy, imaging guidance, acoustic parameters, and biological rationale.
Control
Use credible sham, blinded assessment, and reproducible device calibration.
Outcome
Measure meaningful function and symptoms beyond acute target engagement.
Safety
Use specialist screening, monitoring, emergency planning, and long-term adverse-event follow-up.
Research and clinical readout
Research status
Low-intensity focused ultrasound is being studied as a non-invasive way to influence deep neural targets, with early human work showing feasibility or target engagement but not yet general clinical efficacy.
Signal confidence
Grade D (Early evidence for feasibility and selected target-engagement signals; low for durable symptom improvement, consumer use, or cognitive enhancement.)
Key question
Can targeting, acoustic dosing, sham control, and monitoring be standardized well enough to produce reproducible patient-important outcomes?
Clinical perspective
Brain ultrasound belongs in specialized research or clinical environments with imaging, acoustic expertise, screening, and adverse-event plans.
Clinical uncertainty
Which targets and indications are mature enough for definitive randomized trials and how much repetition is safe.
Community patterns
Interest centers on deep-brain access without surgery and the possibility of treating mood, pain, movement, or cognition.
Common community failure mode
Assuming a consumer ultrasound device can reproduce MRI-guided clinical parameters.
Where this is heading
Closed-loop targeting, better sham designs, individualized skull modeling, and larger randomized trials will determine whether the platform moves beyond proof of concept.
What to track next
Low-intensity transcranial focused ultrasound uses acoustic energy to target deep neural structures and is being studied for target engagement, pain, movement disorders, and psychiatric symptoms.
Protocol and safety scaffold
Risk gate: No home brain-ultrasound experimentation. This is a specialist research and clinical technology domain.
Baseline first
- Document target, imaging guidance, acoustic parameters, device calibration, sham, and indication.
- Review neurological history, medication, seizure risk, and emergency procedures.
Implementation pattern
- Use only qualified operators and approved study or clinical pathways.
- Require blinded assessment and meaningful functional outcomes beyond acute sensations.
Monitor
- Target engagement, symptoms, neurological status, headache, mood, cognition, and delayed adverse effects.
- Device logs, positioning, acoustic dose, and protocol deviations.
Pause or stop rules
- Stop for new neurological symptoms, severe headache, seizure-like activity, confusion, or unexpected mood change.
- Do not improvise frequency, intensity, target, or session duration.
Clinician gate
Use specialist neurology, psychiatry, pain, or research oversight appropriate to the target and indication.
Glossary connections
Controversies to monitor
Controversies
- Commercial neuromodulation claims outrunning dosimetry and clinical validation.
- Deep-target access raising consent, identity, and enhancement-governance questions.
Core reference classes
Research classes
- 2025 MRI-guided amygdala tFUS target-engagement study
- 2025 sham-controlled ultrasound neuromodulation pilot
Evidence timeline
Linked records are ordered by publication year. A newer record is not automatically stronger; design, population, and endpoint still determine weight.
Low-Intensity Transcranial Focused Ultrasound Amygdala Neuromodulation
PubMed / Target-engagement and clinical feasibility study - Double-blind sham-controlled target-engagement study with single-arm treatment phase
An MRI-guided low-intensity focused-ultrasound study examined amygdala target engagement and short clinical feasibility in mood, anxiety, and trauma-related disorders, motivating but not replacing larger randomized efficacy trials.
View source recordTopic assessment
These questions test evidence interpretation and safety boundaries, not personal medical decisions.
1. What is the most defensible first question when evaluating Transcranial Focused Ultrasound Neuromodulation?
Show answer and explanation
What outcome, evidence, and risk boundary are defined?
A clear outcome, evidence design, and risk boundary keep an encyclopedia claim from becoming an unsafe recommendation.
2. What would make a claim about Transcranial Focused Ultrasound Neuromodulation more trustworthy?
Show answer and explanation
Replication with appropriate controls, context, and meaningful outcomes
Reproducibility and patient-important outcomes matter more than novelty, complexity, or an isolated signal.
Editorial update history
This log records what changed in the encyclopedia record and why the update matters for interpretation.
A-Z topic scaffolding, safety framing, learning paths, and linked evidence architecture established for the living encyclopedia.
Added distinct dossiers for continuous glucose monitoring, GLP-1 and incretin therapeutics, metformin geroscience, rapamycin and mTOR, transcranial focused ultrasound, polygenic risk scores, digital phenotyping, and psychedelic microdosing, with evidence lanes and explicit medical and governance boundaries.
Related record update: Low-Intensity Transcranial Focused Ultrasound Amygdala Neuromodulation
Linked evidence records
Low-Intensity Transcranial Focused Ultrasound Amygdala Neuromodulation
PubMed / Target-engagement and clinical feasibility study • Double-blind sham-controlled target-engagement study with single-arm treatment phase • Published: 2025 • Checked: Aug 17, 2026
An MRI-guided low-intensity focused-ultrasound study examined amygdala target engagement and short clinical feasibility in mood, anxiety, and trauma-related disorders, motivating but not replacing larger randomized efficacy trials.
How to interpret this record
What it supports
The study provides early human evidence about MRI-guided tFUS target engagement, feasibility, and short-term clinical signals in a defined psychiatric research population.
Major limitations
The target-engagement phase and unblinded treatment phase have different evidentiary strength, and the study requires larger randomized efficacy and safety trials.
What it does not establish
The study does not establish home ultrasound, general cognitive enhancement, or safe neuromodulation outside qualified clinical research.